[SIME] YoY Quarter Result on 31-Dec-2013 [#2]

Stock
[SIME] SIME DARBY BHD
Announcement Date
28-Feb-2014
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2014
Quarter
31-Dec-2013 [#2]
Profit Trend
QoQ- 67.35%
YoY- 15.49%
Quarter Report
Latest QR
Upcoming QR
SIME's Result
SIME's Financial Summary
View:
Show?
Quarter Result
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Revenue 8,086,000 11,828,943 10,741,990 10,708,360 11,254,132 11,389,297 9,993,651 -3.46%
PBT 287,000 463,546 592,700 953,223 1,010,082 1,623,523 1,248,015 -21.70%
Tax 422,000 -139,604 -127,943 -93,621 -273,555 -462,617 -325,073 -
NP 709,000 323,942 464,757 859,602 736,527 1,160,906 922,942 -4.29%
-
NP to SH 653,000 273,285 437,395 818,311 708,539 1,101,380 877,058 -4.79%
-
Tax Rate -147.04% 30.12% 21.59% 9.82% 27.08% 28.49% 26.05% -
Total Cost 7,377,000 11,505,001 10,277,233 9,848,758 10,517,605 10,228,391 9,070,709 -3.38%
-
Net Worth 36,072,640 30,930,892 27,723,928 26,395,189 25,901,637 24,829,146 21,986,522 8.59%
Dividend
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Div 397,860 372,661 363,990 360,754 420,676 601,189 480,579 -3.09%
Div Payout % 60.93% 136.36% 83.22% 44.09% 59.37% 54.59% 54.79% -
Equity
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Net Worth 36,072,640 30,930,892 27,723,928 26,395,189 25,901,637 24,829,146 21,986,522 8.59%
NOSH 6,800,839 6,211,022 6,066,504 6,012,571 6,009,660 6,011,899 6,007,246 2.08%
Ratio Analysis
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
NP Margin 8.77% 2.74% 4.33% 8.03% 6.54% 10.19% 9.24% -
ROE 1.81% 0.88% 1.58% 3.10% 2.74% 4.44% 3.99% -
Per Share
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
RPS 121.94 190.45 177.07 178.10 187.27 189.45 166.36 -5.04%
EPS 9.80 4.40 7.21 13.61 11.79 18.32 14.60 -6.42%
DPS 6.00 6.00 6.00 6.00 7.00 10.00 8.00 -4.67%
NAPS 5.44 4.98 4.57 4.39 4.31 4.13 3.66 6.82%
Adjusted Per Share Value based on latest NOSH - 6,012,571
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
RPS 118.70 173.64 157.69 157.19 165.21 167.19 146.70 -3.46%
EPS 9.59 4.01 6.42 12.01 10.40 16.17 12.87 -4.78%
DPS 5.84 5.47 5.34 5.30 6.18 8.83 7.05 -3.08%
NAPS 5.2953 4.5405 4.0698 3.8747 3.8023 3.6448 3.2275 8.59%
Price Multiplier on Financial Quarter End Date
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Date 30/12/16 31/12/15 31/12/14 31/12/13 31/12/12 30/12/11 30/12/10 -
Price 8.10 7.75 9.19 9.52 9.52 9.20 8.80 -
P/RPS 6.64 4.07 5.19 5.35 5.08 4.86 5.29 3.85%
P/EPS 82.25 176.14 127.46 69.95 80.75 50.22 60.27 5.31%
EY 1.22 0.57 0.78 1.43 1.24 1.99 1.66 -4.99%
DY 0.74 0.77 0.65 0.63 0.74 1.09 0.91 -3.38%
P/NAPS 1.49 1.56 2.01 2.17 2.21 2.23 2.40 -7.63%
Price Multiplier on Announcement Date
31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 31/12/10 CAGR
Date 27/02/17 24/02/16 26/02/15 28/02/14 27/02/13 29/02/12 24/02/11 -
Price 9.07 7.64 9.37 9.11 9.17 9.69 9.02 -
P/RPS 7.44 4.01 5.29 5.12 4.90 5.11 5.42 5.41%
P/EPS 92.10 173.64 129.96 66.94 77.78 52.89 61.78 6.87%
EY 1.09 0.58 0.77 1.49 1.29 1.89 1.62 -6.38%
DY 0.66 0.79 0.64 0.66 0.76 1.03 0.89 -4.85%
P/NAPS 1.67 1.53 2.05 2.08 2.13 2.35 2.46 -6.24%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment